Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry

mAbs

Volumn 6, Issue 6, 2014, Pages 1474-1485

  Zhu, Lei ^a,b   Guo, Qingcheng ^a,b   Guo, Huaizu ^a,b   Liu, Tao ^a,b   Zheng, Yingxin ^a,b   Gu, Peiming ^b   Chen, Xi ^d   Wang, Hao ^a,b,c   Hou, Sheng ^a,b,c   Guo, Yajun ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b State Key Laboratory of Antibody Medicine and Targeted Therapy Shanghai Key Laboratory of Cell Engineering ^*  (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d WATERS CORPORATION   (United States)

Author keywords

Characterization; CTLA4 Ig fusion protein; Glycan; Glycosylation modification; Intact protein; Mass spectrometry; Peptide mapping; Similarity

Indexed keywords

ABATACEPT; GLYCAN; ANTIBODY CONJUGATE; BIOSIMILAR AGENT; GLYCOPEPTIDE; POLYSACCHARIDE;

ARTICLE; CONTROLLED STUDY; ELECTRON TRANSPORT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PEPTIDE MAPPING; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; AMINO ACID SEQUENCE; GLYCOSYLATION; HUMAN; METABOLISM; MOLECULAR GENETICS; PROCEDURES;

AMINO ACID SEQUENCE; BIOSIMILAR PHARMACEUTICALS; CHROMATOGRAPHY, LIQUID; GLYCOPEPTIDES; GLYCOSYLATION; HUMANS; IMMUNOCONJUGATES; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES;

EID: 84920832247     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.36313     Document Type: Article

References (39)

1. Reichert JM. Marketed therapeutic antibodies compendium. mAbs 2012; 4:413-5; PMID:22531442; http:// dx.doi.org/10.4161/mabs.19931
2. Un utzer J, Schoenbaum M, Katon WJ, Fan MY, Pincus HA, Hogan D, Taylor J. Healthcare costs associated with depression in medically Ill fee-for-service medicare participants. J Am Geriatr Soc 2009; 57:506-10; PMID:19175438; http://dx.doi.org/10.1111/j.1532-5415.2008.02134.x
3. Belsey MJ, Harris LM, Das RR, Chertkow J. Biosimilars: initial excitement gives way to reality. Nat Rev Drug Discov 2006; 5:535-6; PMID:16883647; http:// dx.doi.org/10.1038/nrd2093
4. Sockolosky JT, Tiffany MR, Szoka FC. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci USA 2012; 109: 16095-100; PMID:22991460; http://dx.doi.org/ 10.1073/pnas.1208857109
5. Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, ChenW, Mazzeo JR. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. mAbs 2010; 2:379-94; PMID:20458189; http://dx.doi.org/ 10.4161/mabs.11986
6. Chen RC, Naiyanetr P, Shu SA, Wang J, Yang GX, Kenny TP, Guggenheim KC, Butler JD, Bowlus C, Tao MH. Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology 2013; 57:1498-508; PMID:23184636; http://dx.doi.org/10.1002/hep.26157
7. Declerck PJ. Biosimilar monoclonal antibodies: a sci-ence-based regulatory challenge. Expert Opin Biol Ther 2013; 13:153-6; PMID:23286777; http://dx.doi. org/10.1517/14712598.2012.758710
8. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 2012; 11:527-40; PMID:22743980; http://dx.doi.org/ 10.1038/nrd3746
9. Jez J, Antes B, Castilho A, Kainer M, Wiederkum S, Grass J, Ruker F, Woisetschlager M, Steinkellner H. Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments. J Biol Chem 2012; 287:24313-9; PMID:22589538; http://dx.doi.org/10.1074/jbc.M112.360701
10. Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 2012; 14:554-8; PMID:22610647; http://dx.doi.org/ 10.1208/s12248-012-9369-y
11. Werner RG, Kopp K, SchlueterM. Glycosylation of therapeutic proteins in different production systems. Acta Paediatr Suppl 2007; 96:17-22; PMID:17391433; http://dx. doi.org/10.1111/j.1651-2227.2007.00199.x
12. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012; 526: 159-66; PMID:22465822; http://dx.doi.org/10.1016/ j.abb.2012.03.021
13. Zhu D, McCarthy H, Ottensmeier CH, Johnson P, Hamblin TJ, Stevenson FK. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 2002; 99:3562-8; PMID:11986208; http://dx.doi.org/10.1182/blood. V99.7.2562
14. Lee JW, Forciniti D. Effect of glycosylation on the partition behavior of a human antibody in aqueous twophase systems. Biotechnol Prog 2013; 29:943-50; PMID:23657984; http://dx.doi.org/10.1002/ btpr.1741
15. Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. mAbs 2011; 3:568-76; PMID:22123061; http:// dx.doi.org/10.4161/mabs.3.6.17922
16. Andersen DC, Bridges T, Gawlitzek M, Hoy C. Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activator. Biotechnol Bioeng 2000; 70:25-31; PMID:10940860; http:// dx.doi.org/10.1002/1097-0290(20001005)70:1%3c25:: AID-BIT4%3e3.0.CO;2-Q
17. Butler M. Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by Mammalian cell systems. Cytotechnology 2006; 50: 57-76; PMID:19003071; http://dx.doi.org/10.1007/ s10616-005-4537-x
18. Gadgil HS, Pipes GD, Dillon TM, Treuheit MJ, Bondarenko PV. Improving mass accuracy of high performance liquid chromatographyelectrospray ionization time-of-flight mass spectrometry of intact antibodies. J Am Soc Mass Spectrom 2006; 17:867-72; PMID:16631376; http://dx.doi.org/10.1016/j. jasms.2006.02.023
19. Emery P, Kavanaugh A, Bao Y, Ganguli A, Mulani P. Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Ann Rheum Dis 2014; 0:1-10; PMID:25139667; http://dx.doi.org/10.1136/ annrheumdis-2014-205302
20. Hot A, Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 2011; 70:727-32; PMID:21345813; http://dx.doi.org/10.1136/ard.2010.143768
21. Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2010; 37:234-45; PMID:20080922; http://dx.doi.org/ 10.3899/jrheum.091066
22. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009; 4:7277-85.
23. Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 2009; 20:692-9; PMID:19889530; http://dx.doi.org/ 10.1016/j.copbio.2009.10.010
24. Bongers J, Devincentis J, Fu J, Huang P, Kirkley DH, Leister K, Liu P, Ludwig R, Rumney K, Tao L. Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping. J Chromatogr A 2011; 1218:8140-9; PMID:21978954; http://dx.doi.org/10.1016/j. chroma.2011.08.089
25. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6:1163-73;; http://dx. doi.org/10.1517/14712598.6.11.1161
26. Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, Bobrowicz P, Choi B-K, Cook WJ, Cukan M. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006; 24:210-5; PMID:16429149; http://dx.doi.org/10.1038/nbt1178
27. Eon-Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog 2012; 28:608-22; PMID:22473974; http://dx.doi.org/ 10.1002/btpr.1548
28. Commins SP, Kelly LA, Ronmark E, James HR, Pochan SL, Peters EJ, Lundback B, Nganga LW, Cooper PJ, Hoskins JM. Galactose- a-1, 3-galactose-specific IgE is associated with anaphylaxis but not asthma. Am J Respir Crit Care Med 2012; 185:723-30; PMID:22281828; http://dx.doi.org/10.1164/ rccm.201111-2017OC
29. Beck A, Wagner-Rousset E, Bussat M-C, Lokteff M, Klinguer-Hamour C, Haeuw J-F, Goetsch L, Wurch T, Dorsselaer AV, Corvaïa N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008; 9:482-501; PMID:19075687; http:// dx.doi.org/10.2174/138920108786786411
30. Lammerts van Bueren JJ, Rispens T, Verploegen S, van der Palen-Merkus T, Stapel S, Workman LJ, James H, van Berkel PH, van de Winkel JG, Platts-Mills TA, et al. Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol 2011; 29:574-6; PMID:21747378; http://dx. doi.org/10.1038/nbt.1912
31. Xie H, Gilar M, Chakraborty A, Chen W, Berger S. Monitoring deamidation progression in an antibody tryptic digest using UPLCMSE with BiopharmaLynx and a Xevo QTof MS system. Waters Appl Note 2009 (Milford, Massachusetts); 720002879en
32. Dick LW Jr, Mahon D, Qiu D, Cheng K-C. Peptide mapping of therapeutic monoclonal antibodies: improvements for increased speed and fewer artifacts. J Chromatogr B Technol Biomed Life Sci 2009; 877:230-6; PMID:19112052; http://dx.doi.org/ 10.1016/j.jchromb.2008.12.009
33. Chelius D, Xiao G, Nichols AC, Vizel A, He B, Dillon TM, Rehder DS, Pipes GD, Kraft E, Oroska A. Automated tryptic digestion procedure for HPLCMSMS peptide mapping of immunoglobulin gamma antibodies in pharmaceutics. J Pharm Biomed Anal 2008; 47:285-94; PMID:18313251; http://dx. doi.org/10.1016/j.jpba.2008.01.018
34. Xie H, Gilar M, Gebler JC. Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry. Anal Chem 2009; 81:5699-708; PMID:19518054; http://dx.doi. org/10.1021/ac900468j
35. Castro-Perez JM, Kamphorst J, DeGroot J, Lafeber F, Goshawk J, Yu K, Shockcor JP, Vreeken RJ, Hankemeier T. Comprehensive LC¡ MSE lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J Proteome Res 2010; 9:2377-89; PMID:20355720; http://dx. doi.org/10.1021/pr901094j
36. Chakraborty AB, Berger SJ, Gebler JC. Use of an integrated MS-multiplexed MSMS data acquisition strategy for high-coverage peptide mapping studies. Rapid Commun Mass Spectrom 2007; 21:730-44; PMID:17279597; http://dx.doi.org/10.1002/rcm.2888
37. Royle L, Roos A, Harvey DJ, Wormald MR, van Gijls-wijk-Janssen D, Redwan el RM, Wilson IA, Daha MR, Dwek RA, Rudd PM. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem 2003; 278:20140-53; PMID:12637583; http://dx.doi.org/10.1074/jbc. M301436200
38. Huang Y, Mechref Y, Novotny MV. Microscale nonreductive release of O-linked glycans for subsequent analysis through MALDI mass spectrometry and capillary electrophoresis. Anal Chem 2001; 73:6063-9; PMID:11791581; http://dx.doi.org/10.1021/ ac015534c
39. Bosques CJ, Collins BE, Meador JW III, Sarvaiya H, Murphy JL, DelloRusso G, Bulik DA, Hsu I-H, Washburn N, Sipsey SF, et al. Chinese hamster ovary cells can produce galactose-a-1,3-galactose antigens on proteins. Nat Biotechnol 2010; 28:1153-6; PMID:21057479; http://dx.doi.org/10.1038/nbt1110- 1153